Author: Bella Hayes
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 – REGN Source link
Faruqi & Faruqi Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 – APLT Source link
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Integral Ad Science Holding Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IAS Source link
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Monolithic Power Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MPWR Source link
ROSEN, A LEADING LAW FIRM, Encourages Walgreens Boots Alliance, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBA Source link
ROSEN, A LEADING LAW FIRM, Encourages TELUS International (Cda) Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TIXT Source link
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN Source link
EYLEA HD ® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting Source link
New to The Street Premieres Back-to-Back Episodes on Bloomberg: Episode 624 Aired Last Night, Episode 625 Airs Tonight at 6:30 PM EST as Sponsored Programming Source link
Three-Year Results for EYLEA HD ® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Source link
